We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Illumina

Illumina develops, manufactures and markets integrated systems for the analysis of genetic variations and biological ... read more Featured Products: More products

Download Mobile App




Genetics Influence Risk for Spontaneous Coronary Artery Dissection

By LabMedica International staff writers
Posted on 14 Sep 2020
Spontaneous coronary artery dissection (SCAD) is an increasingly recognized cause of myocardial infarction (MI) in young and otherwise healthy women, for which the etiology is incompletely understood. More...


SCAD is defined as a non-traumatic, non-iatrogenic, and non-atherosclerotic separation of the coronary arterial wall by intramural hemorrhage, most often elicited by spontaneous intimal tear or rupture of vasa vasorum, causing accumulation of intramural hematoma that compresses the true arterial lumen, resulting in compromised coronary artery blood flow and MI.

Cardiologists at the University of Michigan Medical School (Ann Arbor, MI, USA) and their international colleagues performed a genome-wide association study, analyzing millions of genetic markers in patients with SCAD and healthy controls. Genotyping of the different cohort samples were conducted by the University of Michigan DNA Sequencing Core using the Illumina Infinium HTS Assay Protocol, a semi-custom Infinium CoreExome-24v1.1 BeadArray with 607,778 SNP markers, and the Illumina GenomeStudio v2011.1 (Illumina, San Diego, CA, USA).

The investigators found a significant association of several specific genetic regions associated with SCAD, which further implicated specific genes influenced by the identified genetic variants. They identified and replicated an association of rs12740679 at chromosome 1q21.2 influencing ADAMTSL4 expression. In addition, they reported that the genetic risk factors for SCAD also predict SCAD among individuals with fibromuscular dysplasia, or FMD, a vascular disease that may affect any artery in the body and is found in some patients with SCAD. Many people with FMD also lack traditional risk factors underlying atherosclerosis, like high blood pressure and diabetes, but still may be at risk for vascular complications such as arterial aneurysms and dissections. The SCAD risk alleles were positively associated with migraine headache, which highlights a shared genetic basis for migraine headache and SCAD.

Santhi Ganesh, MD, an Associate Professor of Internal Medicine and senior study author, said, “As a physician caring for patients with both FMD and SCAD, it is gratifying to see results from our studies that are beginning to uncover the genetic architecture and risk for these diseases about which so little is known.”

Jacqueline Saw, MD, FRCPC, FACC, an Interventional Cardiologist at the Vancouver General Hospital (Vancouver, BC, Canada) and co-lead author of the study, said, “"Identifying these genetic risk alleles helps further advance our understanding of risks of SCAD. Whether these findings have implications for SCAD in high-risk populations, such as those with peripartum SCAD is an important next step to study.”

The authors concluded that their findings support a hypothesis of vascular pleiotropy with sex-dimorphic effects and warrant further investigation to understand targets for mitigating MI risk due to diverse vascular pathobiology. The study was published on September 4, 2020 in the journal Nature Communications.





Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Hybrid Pipette
SWITCH
8-Channel Pipette
SAPPHIRE 20–300 µL
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The Elecsys pTau-181 test helps rule out Alzheimer’s disease in symptomatic patients aged 55 and older by identifying absence of amyloid pathology (photo courtesy of Roche)

Simple Blood Test Offers New Path to Alzheimer’s Assessment in Primary Care

Timely evaluation of cognitive symptoms in primary care is often limited by restricted access to specialized diagnostics and invasive confirmatory procedures. Clinicians need accessible tools to determine... Read more

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Pathology

view channel
Image: The innovative classifier can guide treatment for PDAC and other immunotherapy-resistant cancers (Photo courtesy of Adobe Stock))

Single Sample Classifier Predicts Cancer-Associated Fibroblast Subtypes in Patient Samples

Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers, in part because of its dense tumor microenvironment that influences how tumors grow and respond to treatment.... Read more

Industry

view channel
Image: QuidelOrtho has entered into a strategic supply agreement with Lifotronic to expand its global immunoassay portfolio (Photo courtesy of QuidelOrtho)

QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio

QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.